INTRODUCTION
============

Glioblastoma is characterized by rapidly dividing cells, high degree of vascularity, invasion into the normal brain tissue, and an intense resistance to death-inducing stimuli. Significant advances have been made in understanding the molecular genetics underlying the heterogeneity of glioblastoma and their resistance to therapies. However, standard therapy including surgical resection and radiotherapy with concomitant and adjuvant chemotherapy using temozolomide (TMZ) remains poorly efficient ([@B110]). Prognostic and predictive markers are continuously proposed based on large scale genomic data. In the recent years, emphasis has been given to the predictive impact of O^6^-methylguanine-DNA methyltransferase (MGMT) expression/activity, a DNA repair enzyme that protects cells against alkylating drugs such as TMZ ([@B108]). The promoter of the MGMT gene is methylated in 40--45% of glioblastoma and the enzyme is not expressed in the majority of these cases ([@B47]; [@B99]). While the contribution of MGMT to TMZ resistance is highly documented, tumors in which MGMT is not the primary determinant of treatment outcome also exist ([@B17]; [@B21]). Integrins have been proposed to play a role in the aggressiveness of gliomas and have been implicated in radio/chemoresistance in different types of tumors ([@B4]). The p53 protein has been largely studied in gliomas but its prognostic value has not been consistently established. In line with our recent data proposing an α~5~β~1~ integrin-p53 axis with potential implication in TMZ resistance ([@B56]), we will summarize here the current knowledge on integrins and p53 status in glioblastoma.

INTEGRINS IN GLIOMA
===================

BIOLOGY OF INTEGRINS
--------------------

Integrins are heterodimeric cell surface receptors that mediate cell adhesion to the extracellular matrix (ECM) and support cell--cell interactions in a multitude of physiological and pathological situations. They are at least 24 known αβ heterodimers formed by a combination of 18 α and 8 β subunits bound non-covalently. Natural ligands of integrins are component of the ECM such as vitronectin, collagen, or fibronectin. Each αβ integrin pair has a defined set of ECM protein ([@B54]). The repertoire of integrins present at the membrane dictates therefore the extent to which a cell will behave on a specific matrix and respond to its environment. Once engaged with the ECM, integrins cluster and recruit various signaling and adaptor proteins to form focal adhesion complexes ([@B39]). These complexes activate intracellular downstream signaling pathways including NF-κB, PI3K, Src, or Ras-MAP kinases ([@B54]; [@B67]). Such pathways regulate functions involved in motility, cytoskeleton organization, adhesion, proliferation, survival, and gene transcription. Integrins link ECM to the actin cytoskeleton through FAK/ILK/SFK/Rho proteins pathway providing the traction necessary for cell motility ([@B39]). Integrins regulate the localization and the activity of urokinase-type plasminogen activator (uPA)/uPA receptor ([@B40]; [@B120]; [@B8]) and matrix metalloproteinases (MMPs; [@B64]; [@B84]) therefore controlling ECM remodeling and the invasive process.

Beside their mechanical functions and despite the lack of intrinsic kinase activity, integrins are true signaling molecules. Integrins regulate proliferation by controlling the expression of cyclin D1 which permits cells to enter the S-phase of the cell cycle ([@B34]). Integrins relay survival or apoptotic signals depending on the surrounding environment. Integrin ligation promote survival through various mechanisms including increased anti-apoptotic proteins (bcl-2, FLIP; [@B3]; [@B78]; [@B117]), activation of PI3K--Akt ([@B2]) or NF-κB pathway ([@B95]; [@B24]). Unligated integrins were reported to promote apoptosis through the so-called integrin-mediated death (IMD) a mechanism dependent, or not, on caspases activation in anchorage-dependent cells ([@B107]; [@B55]). However, tumor cells are often IMD-resistant and unligated integrins rather promote anchorage-independent growth, survival, and metastasis than apoptosis ([@B29]). Additionally, cross-talks occur between integrins, cytokines, and growth factor receptors. Optimal growth factor stimulation relies on integrin-mediated adhesion to an appropriate ECM protein. α~v~β~3/5~ and α~5~β~1~ interact with growth factor receptors (VEGFR2, c-Met, FGFR1, PDGFR, EGFR, TIE-2, and IGF-1R) to promote full activation of each receptor and maximal signal transduction (increased MAPK and Akt activity) resulting in enhanced cell migration, proliferation, survival, and angiogenesis ([@B37]; [@B32]; [@B1]; [@B103]). Integrins were also reported to bind directly growth factor (such as angiopoietins or VEGF) allowing the transduction of information in the absence of the receptor ([@B18]; [@B53]). In short, integrins sense, interpret, and distribute information so that cancer cells adjust and respond to their microenvironment.

INTEGRIN EXPRESSION AND FUNCTION IN GLIOMA
------------------------------------------

Clustering of transcriptomic data from high grade glioma predicted poor survival in subclasses of tumors overexpressing ECM components such as fibronectin which is the preferred ligand of α~5~β~1~ and α~v~β~3~ integrins ([@B39]; [@B35]; [@B13]; [@B20]; [@B115]). Functional analysis revealed gliomagenesis and glioblastoma networks composed of genes that play a role in integrin signaling including fibronectin, α~3~ and α~5~ integrins ([@B13]). [@B41] investigated glioblastoma for the expression of cell adhesion molecules including integrins that might distinguish tumor from normal adjacent brain tissue. Results showed that glioblastoma expressed α~2~, α~3~, α~5~, α~6~β~1~, and α~v~β~3~ integrins at significantly higher level than normal brain tissue suggesting that these integrins might play a role in the development or the progression of glioma ([@B41]). β~8~ and α~5~β~1~ integrins were commonly expressed in a perinecrotic or perivascular pattern in glioblastoma ([@B90]). Higher levels of α~5~ and β~3~ integrin mRNA were measured in glioblastoma as compared to normal brain or low grade astrocytoma ([@B62]). Average α~v~β~3~ integrin expression in glioblastoma seemed to exceed those in low grade glioma at the protein level although mRNA levels of both subunits were not discriminative between glioblastoma and low grade glioma ([@B97]). In another study, α~v~β~5~ and α~5~β~1~ integrins were shown to be expressed at consistently higher levels than α~v~β~3~ integrins in human glioma cell explants ([@B79]). We and others showed recently that α~5~β~1~ integrin expression in biopsies from patient with glioma correlated with poor prognosis and tumor aggressiveness ([@B23]; [@B52]; [@B56]).

In glioma, integrins were often studied because of their crucial role in tumor cell invasion ([@B46]). Both β~1~ subunit-containing integrins ([@B87]) and α~v~β~3~ integrins control glioma cell invasion ([@B25]). α~2~β~1,~ α~3~β~1~, and α~5~β~1~ integrins are overexpressed in multidrug-resistant glioma cells and are responsible for their increased adhesive and invasive capacities ([@B49]). The laminin-5 receptor α~3~β~1~ integrin is mainly expressed in areas of tumor cell invasion and support glioma cell migration and invasion ([@B116]; [@B74]; [@B59]). α~v~β~3~ integrins promote migration and adhesion in various glioma cells ([@B42]; [@B36]) and inhibition of α~v~β~3~ integrin with neutralizing antibody inhibited migration and invasion selectively in cell lines that contained a high level of integrin expression ([@B122]). Our laboratory extensively investigated α~5~β~1~ integrins in glioma. We showed that α~5~β~1~ integrins increased proliferation, clonogenic survival, adhesion, migration, and invasion of various glioma cell lines ([@B72]; [@B7]; [@B75]; [@B23]). We also reported that the expression of α~5~β~1~ integrins in glioma is controlled by caveolin-1 ([@B75]; [@B23]). Interestingly, it was shown recently that invasive recurrent glioblastoma, resistant to antiangiogenic therapy, overexpress α~5~β~1~ integrin and its ligand fibronectin ([@B28]). α~v~β~3~ integrin/ILK/RhoB pathway ([@B83]) and β~1~ integrin/AKT/p130Cas/paxillin ([@B22]) controlled the radiosensitivity of glioma cells by regulating radiation-induced cell death. Recruitment of α~v~β~3/5~ integrin in glioblastoma cells is induced by hypoxia. It follows the activation of FAK/RhoB/GSK3β pathway leading to HIF-1α induction and the transcription of proangiogenic factors ([@B101]). Finally, surface expression of α~6~β~1~ integrin in U87MG cells enhanced cell spreading and attachment on laminin-111, increased proliferation, decreased apoptosis due to serum starvation and increased migration and invasion of U87MG cells both *in vitro* and *in vivo* ([@B27]).

INTEGRINS IN GLIOMA ANGIOGENESIS
--------------------------------

Induction of angiogenesis is essential for a tumor to grow beyond 1--2 mm and glioblastoma exhibit prolific angiogenesis. Poorly expressed in resting endothelial cells, α~5~β~1~ and α~v~β~3/5~ integrins are highly upregulated on endothelium cells during tumor angiogenesis ([@B16]; [@B5]; [@B30]) and rapidly accessible in tumor blood vessels ([@B73]). They stimulate endothelial cell proliferation, promote migration, and lumen formation ([@B81]). Although α~5~β~1~ integrin is undoubtedly recognized as a proangiogenic factor, controversial results for αvβ3 integrin questioned its role ([@B51]; [@B91]). Overexpression of α~v~β~3~ integrin in glioma exerted growth-suppressive effects *in vivo* that are linked to vascular defects ([@B88]; [@B58], [@B57]). However, antagonists to both α~5~β~1~ and α~v~β~3/5~ integrins are able to inhibit tumor angiogenesis ([@B14]; [@B37]; [@B61]).

INTEGRINS IN GLIOMA STEM CELLS
------------------------------

Brain tumors also contain highly tumorigenic and therapeutically resistant pluripotent stem cells referred as glioma stem or initiating cells. The glioma stem cell hypothesis incorporates a model in which only a small subset of cells, the glioma stem cells, can initiate tumor. This hypothesis was confirmed very recently *in vivo* ([@B66]). Elevated levels of α~6~β~1~ integrins were found in glioma stem cells and seem to be a reliable new marker to enrich for glioma stem cells ([@B65]).

Integrins are implicated at various levels of glioma development and progression. Blocking their functions may affect both tumoral cells and endothelial cells and these characteristics made them attractive therapeutic targets for glioblastoma ([@B19]; [@B45]). Emphasis on α~v~β~3~ integrins has been given recently as cilengitide, their prototypical small peptide antagonist, is currently evaluated in phase III clinical trials in glioblastoma ([@B112]). Interestingly, the outcome in a phase II trial was particularly good in patients with a methylated MGMT gene promoter ([@B109]). Emerging data showing the role of α~5~β~1~ integrin in glioblastoma give some hope for new therapeutic propositions in the near future.

p53 PROTEIN IN GLIOMA
=====================

p53, the "guardian of the genome," is certainly one of the most widely studied protein in human glioma. Activation of the tumor suppressor p53 by stress signals triggers different cellular programs such as cell cycle arrest, apoptosis, differentiation, DNA repair, autophagy, and senescence through complex network and signaling pathways ([@B69]; [@B119]; [@B111]). Gaining a better understanding of how transcriptional and non-transcriptional functions of p53 integrate will be of great importance for the proposal of new therapeutic options ([@B26]; [@B104]). Somatic p53 missense mutations are found in approximately 50% of all human cancers. Intensive research on p53 status as a classical molecular marker led to controversial results and non-significant clinical impact, particularly in the glioma field.

p53 STATUS IN GLIOMA
--------------------

As most mutations in p53 gene led to the accumulation of p53 in the nucleus, nuclear overexpression of p53 was usually considered as a marker of mutation. Several studies showed that the expression of p53 is correlated at 90% with its mutation ([@B33]). Detection of p53 mutation by the yeast functional assay that measures quantitatively mutant p53 alleles and qualitatively the loss of p53 competence was also employed and compared to conventional techniques including DNA sequencing ([@B113]; [@B38]). Overall results indicate that p53 mutations often occurred in low grade gliomas (WHO grade II astrocytoma; [@B12]) and thus is a frequent event in the pathological progression of secondary glioblastoma (WHO Grade IV; [@B43]). Secondary glioblastoma arise from a preexisting grade II or III astrocytoma in contrast with primary glioblastoma that form *de novo*. Primary glioblastoma represent about 90% of glioblastoma. p53 gene mutations are present in about 30% of primary glioblastoma, and occur more frequently in secondary glioblastoma (65%; [@B86]; [@B126]). A recent integrated genomic analysis identified four relevant subclasses of glioblastoma (proneural, mesenchymal, neural, and classical glioblastoma). p53 mutation was observed in 54, 32, 21, and 0% of tumors from the proneural, mesenchymal, neural, and classical glioblastoma subtype, respectively ([@B118]). Interestingly, classical glioblastoma benefit from more aggressive therapy regimen than the others ([@B118]). In fact, the prognostic value of p53 status may be reconsidered according to these data.

p53 STATUS AND GLIOBLASTOMA PROGNOSIS
-------------------------------------

No clear consensus has been reached about the prognostic value of p53 status despite numerous studies (**Table [1](#T1){ref-type="table"}**). A clear picture remains difficult to draw due to the different techniques used to evaluate p53 (including immunostaining on tumor tissues, direct sequencing of p53 gene, and functional assays) and the complexity of patient cohort composition. Data illustrating an association of p53 with survival always point to a longer survival when p53 is mutated ([@B114]; [@B96]; [@B9]; [@B15]). However, the majority of studies do not validate p53 as an independent prognostic marker for glioblastoma ([@B63]; [@B100]; [@B98]; [@B89]; [@B94]; [@B121]; [@B68]; [@B93]). Overall it means that the prognostic impact of p53 aberrations is only marginal when considered in a global glioblastoma patient population. Reevaluation of this impact in clinically relevant glioblastoma subpopulations (see above) and association with specific molecular signatures will certainly be of interest in the future.

###### 

Evaluation of p53 status in glioblastoma.

  Evaluation of the p53 status        Number of patients        \% of p53 mutant   p53: prognostic marker?                                       Reference
  ----------------------------------- ------------------------- ------------------ ------------------------------------------------------------- -----------
  Sequencing/yeast functional assay   42                        43                 YES (longer survival for patients with p53mut tumors)         [@B114]
  Sequencing                          75                        32                 YES (longer survival for patients with p53mut tumors)         [@B96]
  Sequencing/immunostaining           110                       19                 NO                                                            [@B100]
  Sequencing/immunostaining           93                        22                 NO                                                            [@B63]
  Sequencing/yeast functional assay   123                       31                 NO                                                            [@B98]
  Sequencing/immunostaining           41 long-term survivors    25                 YES (longer survival for patients with p53 positive tumors)   [@B15]
                                      48 short-term survivors   31                                                                               
  Immunostaining                      114                       /                  YES (longer survival for patients with p53 positive tumors)   [@B9]
  Sequencing                          41                        27                 NO                                                            [@B89]
  Sequencing/immunostaining           194                       /                  NO                                                            [@B94]
  Sequencing/immunostaining           291                       15                 NO                                                            [@B121]
  Immunostaining                      77 Meta analysis          /                  NO                                                            [@B68]
  Immunostaining                      106                       /                  NO                                                            [@B93]

p53 AND GLIOMA-INITIATING STEM CELLS
------------------------------------

Recent studies begin to shed light onto the role of p53 in the regulation of neural stem cells (NSCs). NSCs are self-renewing cells in the central nervous system that can generate both neurons and glia. An elegant study showed that dual inactivation of p53 and PTEN in murine NSC promotes an undifferentiated state with high renewal potential and generates tumors with a high grade glioma phenotype ([@B126]). Although the role of p53 in brain tumor stem cells has not been well established, data suggest that loss of differentiation and increase in neurosphere renewal may be linked to the disruption of the p53 pathway in glioma ([@B82]; [@B80]; [@B105]). To achieve a permanent eradication of brain tumors, it is noteworthy that glioma-initiating stem cells have to be considered and in this way their p53 status and functions need to be further explored.

p53 AND TMZ
-----------

Despite expressing mainly a wild-type p53 and thus being expected to be sensitive to DNA-damaging agents, primary glioblastoma resist standard therapies including chemotherapy with TMZ. This intriguing observation is in debate and the role of p53 status in response to TMZ has been largely addressed in preclinical studies. Conflicting results have been obtained (**Table [2](#T2){ref-type="table"}**) and show either an improved capability of TMZ to inhibit cell viability when p53wt is functionally inhibited ([@B50]; [@B125], [@B123],[@B124]; [@B31]; [@B10]) or a sensitization of cells to drugs when p53wt is functional ([@B48]; [@B92]). The former studies suggested that glioma cells with an intact p53 gene are selectively impaired in the proapoptotic functions of p53wt while retaining the potential to mediate relevant DNA repair and cell cycle arrest. Treatment with TMZ induced a persistent cell cycle arrest and an increase in p21 (a cell cycle regulator) in functional p53-expressing cells which showed morphological and biochemical features of senescent cells ([@B50]; [@B77]). In cells impaired for p53 function or with a mutant p53, TMZ induced a transient cell cycle arrest and cell death via apoptosis or mitotic catastrophe ([@B50]; [@B77]) as well as attenuation of DNA repair ([@B124]). When TMZ-triggered apoptosis was reported for both p53wt and p53mutant cells, pathways involved differed with activation of the FAS apoptotic pathway or the mitochondrial apoptotic pathway, respectively ([@B92]). Thus adverse effects of p53wt activities are increasingly recognized and may participate in chemoresistance of diverse cancers including glioma ([@B60]; [@B76]). In one recent report, the effect of p53 status on response to TMZ was explored in glioma-initiating stem cells. It was shown that tumor stem cells are resistant to TMZ when p53 is mutated and sensitive to TMZ when intact ([@B10]). These data add a new level of complexity in the relationship between p53 status and TMZ sensitivity in glioma.

###### 

Role of p53 inTMZ outcome.

  Material                                                 p53 inhibition      Effect of p53 modulation onTMZ sensibility   Reference
  -------------------------------------------------------- ------------------- -------------------------------------------- -----------
  Glioblastoma cell lines (U87MG, LNZ308)                  By oncoprotein E6   Increased sensibility                        [@B50]
  Glioblastoma cell lines (SWB95, SWB77, SWB33,                                p53-independent cell cycle arrest            [@B11]
  SWB40, SWB39, SWB61, D54) xenografts                                                                                      
  Glioblastoma cell lines (U87MG, LNZ308)                  By pifithrin-α      Increased sensibility                        [@B123]
  Glioblastoma cell lines (D54, A172)                      By oncoprotein E6   Increased sensibility                        [@B124]
  Glioblastoma cell lines (U87MG, U373MG, U251MG,          By siRNA            Decreased sensibility                        [@B48]
  U138MG, LN18, LN428, LN319, LNT229, LN308,                                                                                
  D247MG,T98G)                                                                                                              
  Glioblastoma cell lines (U87MG, U138MG)                  By pifithrin-α      Decreased sensibility                        [@B92]
  Glioblastoma cell lines (U87MG) xenografts of biopsies   By pifithrin-α      Increased sensibility                        [@B31]
  Glioblastoma cell lines (U87MG, LNZ308, LN443, SF767,    By siRNA            In cell lines : increased sensibility        [@B10]
  U251N, U373)                                                                                                              
  Cancer stem cells                                                            In stem cells : decreased sensibility        

INTEGRINS AND p53
=================

Although p53 itself is functional in a great majority of primary glioblastoma, inactivation of the p53 signaling pathway occurred in the form of ARF deletions, amplifications of mdm2 or mdm4 leading to p53 signaling alterations in 87% of glioblastoma ([@B85]). Additionally several oncogenes such as the glioma oncoprotein Bcl2L12 ([@B106]) were reported to be overexpressed in p53wt tumors and to impair p53 signaling pathway. Few reports investigated the relationship between integrins and p53 signaling pathways. Both integrin-dependent activation ([@B70]) and inhibition ([@B6]) of p53 signaling have been suggested in different tumoral settings except gliomas. For example, Stromblad and colleagues demonstrated that α~v~β~3~ integrin impacts negatively on p53wt activity in melanoma cells ([@B6]; [@B102]). We proposed recently that α~5~β~1~ integrin plays a similar role in high grade glioma ([@B56]). We demonstrated that overexpression of the α~5~ integrin subunit in p53wt U87MG cells impaired the activation of p53 and its transcriptional activity in response to TMZ. Under such conditions, cells became resistant to this alkylating agent. No such effects were found in p53 mutant glioma cell lines. Interestingly, higher levels of α~5~ integrin were found in p53wt tumor biopsies than in p53 mutant tumor biopsies suggesting a link between this specific integrin and p53 status *in vivo*. Our *in vitro* studies also demonstrated that SJ749 and K34c, two specific non-peptidic antagonists of α~5~β~1~ integrin, improved the therapeutic action of TMZ in a p53-dependent way ([@B77]). Molecular pathways involved in the integrin-dependent chemoresistance in p53wt tumors are currently unknown and deserve further studies. Proteins implicated in integrin signaling have been shown to shuttle between the membrane and the nucleus providing a potential mechanism for communication between integrins and p53. In particular FAK, the main kinase activated by integrins, is known to interfere with p53 activity in the nucleus ([@B71]; [@B44]). It will also be interesting to discriminate the potential effect of α~5~β~1~ integrin on transcriptional and non-transcriptional functions of p53. Our data are the first to demonstrate relationships between an integrin and the TMZ-dependent activation of p53 in glioma possibly explaining the resistance to TMZ of a subgroup of patients. It is tempting to suggest that inhibition of α~5~β~1~ integrin by specific antagonists might be an adjuvant treatment to standard therapies in patients expressing high level of α~5~β~1~ integrin and p53wt.

CONCLUSION
==========

Despite few and sometimes conflicting data available both on integrin expression and p53 status as prognostic and/or predictive markers for high grade glioma, a reevaluation of their roles is warranted. Due to the growing knowledge on glioblastoma heterogeneity and subclassification, it becomes reasonable to address these questions more accurately in well defined subpopulations of patients. Key issues need still to be addressed before proposing α~5~β~1~ integrin expression level and p53 status as relevant biomarkers to stratify group of patients which may be more responsive to TMZ.
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